144 related articles for article (PubMed ID: 27708434)
21. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
[TBL] [Abstract][Full Text] [Related]
22. Downregulated Expression of E-cadherin and TP53 in Patients with Gastric Diseases: the Involvement of H. pylori Infection and Its Virulence Markers.
Ferraz MA; Zabaglia LM; Pereira WN; Orcini WA; de Labio RW; Caleman Neto A; Wisnieski F; Calcagno DQ; Santos LC; Assumpção PP; Burbano RR; Artigiani R; Smith Mde A; Payão SL; Rasmussen LT
J Gastrointest Cancer; 2016 Mar; 47(1):20-6. PubMed ID: 26585943
[TBL] [Abstract][Full Text] [Related]
23. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
Mafficini A; Amato E; Cataldo I; Rusev BC; Bertoncello L; Corbo V; Simbolo M; Luchini C; Fassan M; Cantù C; Salvia R; Marchegiani G; Tortora G; Lawlor RT; Bassi C; Scarpa A
Ann Surg; 2018 Jan; 267(1):149-156. PubMed ID: 27611608
[TBL] [Abstract][Full Text] [Related]
24. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
26. Decreased expression of Sox7 correlates with the upregulation of the Wnt/β-catenin signaling pathway and the poor survival of gastric cancer patients.
Cui J; Xi H; Cai A; Bian S; Wei B; Chen L
Int J Mol Med; 2014 Jul; 34(1):197-204. PubMed ID: 24788044
[TBL] [Abstract][Full Text] [Related]
27. TP53 and gastric carcinoma: a review.
Fenoglio-Preiser CM; Wang J; Stemmermann GN; Noffsinger A
Hum Mutat; 2003 Mar; 21(3):258-70. PubMed ID: 12619111
[TBL] [Abstract][Full Text] [Related]
28. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
29. KDM4C-mediated senescence defense is a targetable vulnerability in gastric cancer harboring TP53 mutations.
Wang K; Gong Z; Chen Y; Zhang M; Wang S; Yao S; Liu Z; Huang Z; Fei B
Clin Epigenetics; 2023 Oct; 15(1):163. PubMed ID: 37848946
[TBL] [Abstract][Full Text] [Related]
30. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
31. Gene mutations in gastric cancer: a review of recent next-generation sequencing studies.
Lin Y; Wu Z; Guo W; Li J
Tumour Biol; 2015 Sep; 36(10):7385-94. PubMed ID: 26364057
[TBL] [Abstract][Full Text] [Related]
32. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
Ma X; Wang B; Wang X; Luo Y; Fan W
PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
[TBL] [Abstract][Full Text] [Related]
33. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
34. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
35. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
[TBL] [Abstract][Full Text] [Related]
36. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
37. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
38. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
Samulin Erdem J; Skaug V; Bakke P; Gulsvik A; Haugen A; Zienolddiny S
BMC Cancer; 2016 Jan; 16():28. PubMed ID: 26780934
[TBL] [Abstract][Full Text] [Related]
39. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
40. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors.
Ganci F; Conti S; Fontemaggi G; Manciocco V; Donzelli S; Covello R; Muti P; Strano S; Blandino G; Spriano G
OMICS; 2011 Jun; 15(6):375-81. PubMed ID: 21348641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]